Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

“While we have observed statistically compelling results in PTSD/TBI management using CRISPR. Yhe ability to significantly integrate our treatment protocols with those of Halberd/Athena’s medication and monitoring technologies is quite attractive. The WatchDawg monitoring allows us to acquire near real time (NRT) objective data with respect to the administration of CRISPR. From the preliminary data, there’s no question that the LDX formulation adds clear adjunctive relief.”

CEO Dr. Gabe Vlad, Defense Atomics Corp

“The early results of WatchDawg in LDX therapy are compelling and show that dovetailing therapies of many different forms with real data in brain health studies may hold the key to FDA clearance. It is much harder to argue against near real time data as opposed to mere recollections of subjective observations alone.”

Dr. Mark Darrah, Athena GTX

“We look forward to expanded use of LDX, and now that we can actually see the results documented by the WatchDawg technology in military veterans, the benefit in many modalities is limitless. Having commercial packaging of LDX and potentially CRISPR will allow us to market to physician groups even without formal FDA approval under current compounding laws, particularly with our access to, and relationships with, reputable and qualified compounding facilities. This product is useful for myriad disorders from PTSD, anxiety, depression, anger and addiction, to Chronic Covid, Alzheimer’s, Chronic Kidney Disease (CKD), diabetes, and others. It has been shown to be remarkably without side-effects. These benefits are unique and extremely important to a successful endeavor. We now have a large quantity of commercially available product (LDX), enabling our team to aggressively market LDX to physician groups, hospitals, rehab centers…and something we haven’t discussed and will expand on shortly, animal hospitals and clinics. This finally gives us great potential for real income and a go-to-market capability with actual product. This cannot at this point go directly to consumers, and must go through physicians, which is a potential market. Until then, the physician will be highly incentivized to utilize LDX, so that’s a plus.”

William A. Hartman, CEO of Halberd Corporation

“While CRISPR is limited in FDA usage in the United States, the FDA is looking for well-conceived studies to prove efficacy, particularly in areas where little to no other remedy is offered (Right to Try). LDX alone should be a go-to adjunct to all patients with anxiety and PTSD. We welcome the opportunity to clinically verify it.”

Dr. Richard Goulding, Athena Telemedicine Partner

“I have analyzed the preliminary data offered by the first tranche of patients from the WatchDawg pilot study, and realized that this is clearly the best fit for further research and justification for our CRISPR technology to be used in PTSD and those suffering brain injury. With WatchDawg, we can prove efficacy, or at least support it, all while demonstrating safety and efficacy from initial therapeutic intervention forward. What’s exciting to me is the ability to see, thanks to the WatchDawg monitoring technology, real-time therapeutic effects on the individual. With WatchDawg, we would know immediately when something is working or not working, while quantitatively providing real-time data. That’s a game changer. We have recently been awarded significant cash contracts and are thrilled to be able to have the funds to engage in this exciting trial with our new partners. Helping veterans suffering from suicidal ideation and PTSD has always been my fondest wish, especially since I am myself a veteran.”

CEO Dr. Gabe Vlad, Defense Atomics Corp